Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapport Therapeutics (RAPP) Gains from Sales and Divestitures (2024 - 2026)

Rapport Therapeutics (RAPP) has 3 years of Gains from Sales and Divestitures data on record, last reported at $87574.0 in Q1 2026.

  • On a quarterly basis, Gains from Sales and Divestitures rose 64.83% to $87574.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $87574.0, a 64.83% increase, with the full-year FY2025 number at $34750.0, down 94.3% from a year prior.
  • Gains from Sales and Divestitures reached $87574.0 in Q1 2026 per RAPP's latest filing, up from $34750.0 in the prior quarter.
  • Over the last five years, Gains from Sales and Divestitures for RAPP hit a ceiling of $609402.0 in Q4 2024 and a floor of $34750.0 in Q4 2025.
  • A 3-year average of $250906.2 and a median of $181940.5 in 2024 define the central range for Gains from Sales and Divestitures.
  • On a YoY basis, Gains from Sales and Divestitures climbed as much as 154.95% in 2025 and fell as far as 94.3% in 2025.
  • Tracing RAPP's Gains from Sales and Divestitures over 3 years: stood at $609402.0 in 2024, then tumbled by 94.3% to $34750.0 in 2025, then skyrocketed by 152.01% to $87574.0 in 2026.
  • Business Quant data shows Gains from Sales and Divestitures for RAPP at $87574.0 in Q1 2026, $34750.0 in Q4 2025, and $387569.0 in Q3 2025.